Alpha Healthcare Acquisition filed a definitive proxy statement and scheduled an Aug. 24 meeting for stockholders to vote on its proposed merger with Humacyte, a clinical-stage biotechnology platform.
At closing, Humacyte is expected to have a market capitalization of $1.1 billion.
Announced in February, transaction terms call for a common stock PIPE of approximately $175 million that will close simultaneously with the business combination, as well as up to $100 million held in the SPAC’s trust, subject to any redemptions. Additionally, existing Humacyte investors will be subject to a 12-month lockup with 50 percent eligible for sale after six months if certain price thresholds are met.
If approved, Humacyte will trade on the Nasdaq under HUMA.
Humacyte is developing universally implantable bioengineered human tissue at commercial scale. Read more.
